Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

被引：0
|
作者：
Kim Dalziel
Ali Round
Ruth Garside
Ken Stein
机构：
[1] Peninsula Medical School,Peninsula Technology Assessment Group
[2] Universities of Exeter and Plymouth,Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School
来源：
PharmacoEconomics | 2005年 / 23卷
关键词：
Imatinib; Bone Marrow Transplantation; Chronic Myeloid Leukaemia; Blast Crisis; Cytogenetic Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-α or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia.
引用
收藏
页码：515 / 526
页数：11
相关论文
共 50 条
  • [21] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Abruzzese, Elisabetta
    Breccia, Massimo
    Latagliata, Roberto
    BIODRUGS, 2014, 28 (01) : 17 - 26
  • [22] Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
    Gemelli, Maria
    Elli, Elena Maria
    Elena, Chiara
    Iurlo, Alessandra
    Intermesoli, Tamara
    Maffioli, Margherita
    Pungolino, Ester
    Carraro, Maria Cristina
    D'Adda, Mariella
    Lunghi, Francesca
    Anghileri, Michela
    Polverelli, Nicola
    Rossi, Marianna
    Bacciocchi, Mattia
    Bono, Elisa
    Bucelli, Cristina
    Passamonti, Francesco
    Antolini, Laura
    Gambacorti-Passerini, Carlo
    BLOOD RESEARCH, 2020, 55 (03) : 139 - 145
  • [23] Cost-effectiveness of interferon in chronic myeloid leukaemia: Analysis of four clinical studies
    Messori, A
    ANNALS OF ONCOLOGY, 1998, 9 (04) : 389 - 396
  • [24] Fundus leucaemicus as first manifestation of chronic myeloid leukemia. Diagnosis and monitoring with OCT under treatment with imatinib and interferon-α
    Chankiewitz, E.
    Scholz, G. A.
    Spriewald, B. M.
    Mackensen, A.
    Bergua, A.
    OPHTHALMOLOGE, 2010, 107 (04): : 359 - 362
  • [25] Dasatinib Treatment for Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukaemia
    Li, J.
    Xu, G.
    Yu, S.
    He, L.
    Guo, L.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (02) : 337 - 347
  • [26] Nilotinib In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase
    Garnock-Jones, Karly P.
    DRUGS, 2011, 71 (12) : 1579 - 1590
  • [27] Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients
    Singh, Avinash Kumar
    Hussain, Salman
    Ahmed, Rayaz
    Agrawal, Narendra
    Bhurani, Dinesh
    Klugar, Miloslav
    Sharma, Manju
    NEPHROLOGY, 2022, 27 (04) : 318 - 326
  • [28] Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study
    Giles, Francis J.
    Rosti, Gianantonio
    Beris, Photis
    Clark, Richard E.
    le Coutre, Philipp
    Mahon, Francois-Xavier
    Steegmann, Juan-Luis
    Valent, Peter
    Saglio, Giuseppe
    EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (06) : 665 - 673
  • [29] Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia
    Chen, Yilin
    Yin, Hua
    Chen, Lifeng
    Xiong, Yingyuan
    Meng, Li
    Guo, Jingming
    Wang, Haiyan
    Li, Weiming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (02) : E43 - E49
  • [30] Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukaemia
    A Hochhaus
    XH Yan
    A Willer
    R Hehlmann
    MY Gordon
    JM Goldman
    JV Melo
    Leukemia, 1997, 11 : 933 - 939
12345